ZUBQUSAS
Live / Allowed — Notice of allowance issued (as of 21 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 28 Oct 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99465733
- Mark type
- Word mark
- Filed
- 28 Oct 2025
- Published for opposition
- 26 May 2026
- Attorney of record
- Heather A. McDonald
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Vaccines for human use
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 21 Jul 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 May 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 May 2026 — PUBLISHED FOR OPPOSITION
- 20 May 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Apr 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Apr 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 23 Apr 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Feb 2026 — NON-FINAL ACTION E-MAILED
- 04 Feb 2026 — NON-FINAL ACTION WRITTEN
- 04 Feb 2026 — ASSIGNED TO EXAMINER
- 10 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 28 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 28 Oct 2025 — NEW APPLICATION ENTERED